Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ABL1 G250R ABL1 G251D |
Therapy | Nilotinib |
Indication/Tumor Type | oral cavity cancer |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ABL1 G250R ABL1 G251D | oral cavity cancer | no benefit | Nilotinib | Case Reports/Case Series | Actionable | In a clinical case study, Tasigna (nilotinib) treatment resulted in no benefit in a patient with oral cavity cancer harboring ABL1 G250R and G251D (PMID: 28514312). | 28514312 |
PubMed Id | Reference Title | Details |
---|---|---|
(28514312) | Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. | Full reference... |